nach oben

International Urology and Nephrology

Erschienen in:

09.12.2016 | Nephrology - Original Paper

Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?

verfasst von: Anna Gluba-Brzózka, Beata Franczyk, Maciej Banach, Magdalena Rysz-Górzyńska

Erschienen in: International Urology and Nephrology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Significantly increased cardiovascular mortality in patients with chronic kidney (CKD) disease cannot be explained by traditional risk factors. Recent studies revealed that the quality of HDL and LDL cholesterol may be more important than their serum levels. The aim of this study was to assess which LDL and HDL subfractions were more abundant in end-stage renal disease (ESRD) patients and to analyse whether subfraction distribution could be associated with accelerated atherosclerotic processes.

Methods

This study included 50 ESRD patients undergoing dialysis and 20 healthy volunteers. LDL and HDL subfractions were analysed in serum with the use of Lipoprint system. All patients had intima-media thickness (IMT) measured.

Results

Statistically significant differences in subfractions between control and study group were observed in case of: HDL1 (p < 0.0001), HDL2 (p = 0.009), HDL3 (p < 0.0001), HDL4 (p = 0.003), HDL5 (p = 0.01), HDL7 (p < 0.0001), HDL8 (p < 0.0001), HDL9 (p < 0.0001), HDL10 (p < 0.0001), large HDL (p < 0.0001), HDL Small (p < 0.0001) as well as IDL-B (p = 0.014), IDLA (p = 0.011), LDL2 (p = 0.007). Significant differences were also observed in HDL and LDL subfraction distribution between haemodialysis patients with normal and increased IMT: HDL6 (p = 0.020), HDL Large (HDL1-3) (p = 0.017), HDL Intermediate (HDL4-7) (p = 0.017).

Conclusions

This study revealed that ESRD influenced HDL subfractions. In HD patients, large HDL subfractions are more abundant while small HDL fraction is more frequent in healthy persons. It failed to show the influence of end-stage disease on LDL subfraction levels. Shift in HDL subfractions might be responsible for the increased risk of atherosclerosis in CKD patients.

Navab KD, Elboudwarej O, Gharif M, Yu J, Hama SY, Safarpour S et al (2011) Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease. Curr Pharm Des 17(1):17–20CrossRefPubMed

Kon V, Yang H, Fazio S (2015) Residual cardiovascular risk in chronic kidney disease: role of high-density lipoprotein. Arch Med Res 46:379–391CrossRefPubMedPubMedCentral

McCullough PA, Li S, Jurkovitz CT et al (2008) Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J 156:277–283CrossRefPubMed

Suganuma E, Zuo Y, Ayabe N et al (2006) Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction. J Am Soc Nephrol 17:433–441CrossRefPubMed

Kaysen GA (2009) Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr 19:73–77CrossRefPubMed

Matsushita K, van der Velde M, Chronic Kidney Disease Prognosis Consortium et al (2010) Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073–2081CrossRefPubMedPubMedCentral

Wanner C, Krane V, Marz W et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353:238–248CrossRefPubMed

Kones R (2013) Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag 9:617–670CrossRefPubMedPubMedCentral

Palmer SC, Navaneethan SD, Craig JC et al (2014) HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 5:CD007784

10.

Homma K, Homma Y, Shiina Y, Wakino S, Suzuki M, Fujishima S et al (2013) Skew of plasma low- and high-density lipoprotein distributions to less dense subfractions in normotriglyceridemic chronic kidney disease patients on maintenance hemodialysis treatment. Nephron Clin Pract 123(1–2):41–45CrossRefPubMed

11.

Griffin BA, Freeman DJ, Tait GW, Thompson J, Caslake MJ, Packard C et al (1994) Role of plasma triglyceride in the regulation of plasma low-density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 106:241–253CrossRefPubMed

12.

Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, Saegusa H et al (2004) Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol 24:558–563CrossRefPubMed

13.

Homma Y, Michishita I, Hayashi H, Shigematsu H, Kanagawa Lipid Research Group (2010) Effects of low-dose simvastatin on the distribution of plasma cholesterol and oxidized low-density lipoprotein in three ultracentrifugally separated low-density lipoprotein subfractions: 12-month, open-label trial. J Atheroscler Thromb 17:1049–1053CrossRefPubMed

14.

Kaseda R, Jabs K, Hunley TE, Jones D, Bian A, Allen RM et al (2015) Dysfunctional high-density lipoproteins in children with chronic kidney disease. Metabolism 64(2):263–273CrossRefPubMed

15.

Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack C et al (2011) Uremia alters HDL composition and function. J Am Soc Nephrol 22(9):1631–1641CrossRefPubMedPubMedCentral

16.

Tölle M, Huang T, Schuchardt M, Jankowski V, Prüfer N, Jankowski J et al (2012) High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res 94(1):154–162CrossRefPubMed

17.

Yamamoto S, Yancey PG, Ikizler TA, Jerome WG, Kaseda R, Cox B et al (2012) Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 60(23):2372–2379CrossRefPubMed

18.

Maugeais C, Perez A, von der Mark E, Magg C, Pflieger P, Niesor EJ (2013) Evidence for a role of CETP in HDL remodeling and cholesterol efflux: role of cysteine 13 of CETP. Biochim Biophys Acta 1831(11):1644–1650CrossRefPubMed

19.

Rysz J, Gluba A, Fliser D, Speer T, Wiecek A (2014) Chronic kidney disease—different role for HDL? Curr Med Chem 21(25):2910–2916CrossRef

20.

Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M (2007) Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115:459–467CrossRefPubMed

21.

Shimizu M, Furusyo N, Mitsumoto F, Takayama K, Ura K, Hiramine S et al (2015) Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: results from the Kyushu and Okinawa Population Study (KOPS). Atherosclerosis 238(2):207–212CrossRefPubMed

22.

Chonchol M, Gnahn H, Sander D (2008) Impact of subclinical carotid atherosclerosis on incident chronic kidney disease in the elderly. Nephrol Dial Transpl 23:2593–2598CrossRef

23.

Dukát A, Oravec S, Wawruch M, Gavorník P, Sabaka P (2011) The incidence of dyslipidemia in a sample of asymptomatic probands established by the means of Lipoprint system]. Vnitr Lek 57(3):258–260PubMed

24.

Simova I (2015) Intima-media thickness: Appropriate evaluation and proper measurement, described. E-J ESC Counc Cardiol Pract 13(21). http://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-13/Intima-media-thickness-Appropriate-evaluation-and-proper-measurement-described

25.

Moradi H, Vaziri ND, Said HM, Kalantar-Zadeh K (2013) Role of HDL dysfunction in end-stage renal disease: a double-edged sword. J Ren Nutr. 23(3):203–206CrossRefPubMedPubMedCentral

26.

Vaziri ND, Navab K, Gollapudi P, Moradi H, Pahl MV, Barton CH, Fogelman AM, Navab M (2011) Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease. J Natl Med Assoc 103(6):524–533CrossRefPubMedPubMedCentral

27.

Stack AG, Bloembergen WE (2001) Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study. J Am Soc Nephrol 12(7):1516–1523PubMed

28.

Rysz J, Stolarek RA, Pedzik A, Nowicki M, Nowak D (2010) Serum antioxidant capacity is preserved in peritoneal dialysis contrary to its robust depletion after hemodialysis and hemodiafiltration sessions. Ther Apher Dial 14(2):209–217CrossRefPubMed

29.

Rysz J, Potargowicz E, Banach M, Luczyńska M, Stolarek R, Białasiewicz P et al (2006) Increased whole blood chemiluminescence in patients with chronic renal failure independent of hemodialysis treatment. Arch Immunol Ther Exp (Warsz) 54(5):347–355CrossRef

30.

Maeda S, Nakanishi S, Yoneda M, Awaya T, Yamane K, Hirano T et al (2012) Associations between small dense LDL, HDL subfractions (HDL2, HDL3) and risk of atherosclerosis in Japanese-Americans. J Atheroscler Thromb 19(5):444–452CrossRefPubMed

31.

Bjornheded T, Babyi A, Bodjers G, Wiklund O (1996) Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123:43–56CrossRef

32.

Berneis KK, Krauss RM (2002) Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43:1363–1379CrossRefPubMed

33.

Salonen JT, Salonen R, Seppanen K, Rauramaa R, Tuomilehto J (1991) HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction: a prospective study in eastern Finnish men. Circulation 84:129–139CrossRefPubMed

34.

Smuts CM, Weich HF, Weight MJ, Faber M, Kruger M, Lombard CJ et al (1994) Free cholesterol concentrations in the high-density lipoprotein subfraction-3 as a risk indicator in patients with angiographically documented coronary artery disease. Coron Artery Dis 5:331–338CrossRefPubMed

35.

Iwanejko J, Kwasniak M, Wybranska I, Hartwich J, Guevara I, Zdzienicka A et al (1996) Heterogeneity of high-density lipoprotein particles and insulin output during oral glucose tolerance test in men with coronary artery disease. Acta Diabetol 33:58–61CrossRefPubMed

36.

Tsuzaki K, Kotani K, Sano Y, Fujiwara S, Gazi IF, Elisaf M et al (2012) The relationship between adiponectin, an adiponectin gene polymorphism, and high-density lipoprotein particle size: from the Mima study. Metabolism 61(1):17–21CrossRefPubMed

37.

Eisenberg S (1984) High density lipoprotein metabolism. J Lipid Res 25(10):1017–1058PubMed

38.

Yamashita S, Ishigami M, Arai T, Sakai N, Hirano K, Kameda-Takemura K et al (1995) Very high density lipoproteins induced by plasma cholesteryl ester transfer protein CETP have a potent antiatherogenic function. Ann NY Acad Sci 748:606–608CrossRefPubMed

39.

Kontush A, Chantepie S, Chapman MJ (2003) Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23:1881–1888CrossRefPubMed

40.

Favari E, Calabresi L, Adorni MP, Jessup W, Simonelli S, Franceschini G, Bernini F (2009) Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 48:11067–11074CrossRefPubMed

41.

de Souza JA, Vindis C, Nègre-Salvayre A, Rye KA, Couturier M, Therond P, Chantepie S, Salvayre R, Chapman MJ, Kontush A (2010) Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipo-protein A-I. J Cell Mol Med 14:608–620PubMed

42.

Camont L, Lhomme M, Rached F, Le Goff W, Nègre-Salvayre A, Salvayre R, Calzada C, Lagarde M, Chapman MJ, Kontush A (2013) Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 33:2715–2723CrossRefPubMed

43.

Bjornheden T, Babyi A, Bondjers G, Wiklund O (1996) Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 123:43–56CrossRefPubMed

44.

Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ (1998) Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res 39:1263–1273PubMed

45.

Tribble DL, Rizzo M, Chait A, Lewis DM, Blanche PJ, Krauss RM (2001) Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small, dense low-density lipoproteins. Am J Med 110:103–110CrossRefPubMed

46.

Touboul PJ, Labreuche J, Bruckert E, Schargrodsky H, Prati P, Tosetto A et al (2014) HDL-C, triglycerides and carotid IMT: a meta-analysis of 21,000 patients with automated edge detection IMT measurement. Atherosclerosis 232(1):65–71CrossRefPubMed

47.

Kaseda R, Jabs K, Hunley TE, Jones D, Bian A, Allen RM et al (2015) Dysfunctional high-density lipoproteins in children with chronic kidney disease. Metabolism 64(2):263–273CrossRefPubMed

48.

Moradi H, Streja E, Kashyap ML, Vaziri ND, Fonarow GC, Kalantar-Zadeh K (2014) Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrol Dial Transplant 29(8):1554–1562CrossRefPubMedPubMedCentral

49.

Vaziri ND, Navab M, Fogelman AM (2010) HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol 6(5):287–296CrossRefPubMed

50.

Rysz J, Majewska E, Stolarek RA, Banach M, Ciałkowska-Rysz A, Baj Z (2006) Increased levels of soluble TNF-alpha receptors and cellular adhesion molecules in patients undergoing bioincompatible hemodialysis. Am J Nephrol 26(5):437–444CrossRefPubMed

Titel: Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?
verfasst von: Anna Gluba-Brzózka
Beata Franczyk
Maciej Banach
Magdalena Rysz-Górzyńska
Publikationsdatum: 09.12.2016
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 1/2017
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-016-1466-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy

Does the internal inguinal ring need closure during laparoscopic orchiopexy with Prentiss manoeuvre?

Clinical outcomes of acute kidney injury developing outside the hospital in elderly

Socioeconomic status is associated with urinary diversion utilization after radical cystectomy for bladder cancer

Impact of smoking status and cumulative smoking exposure on tumor recurrence of non-muscle-invasive bladder cancer